c-LEcta GmbH
Mathias Bell serves as Vice President Legal, IP & Licensing at c-LEcta GmbH, with responsibilities including business contract drafting, negotiation, contract management, legal assessment, litigation management, and due diligence. In this role, Mathias oversees patent and trademark portfolio management and enforcement, technology licensing, and manages a team of five. Previous positions include Head Legal Affairs & IP and Senior Business Development Manager at c-LEcta GmbH, Consultant IPR Management and Licensing at Ascenion GmbH, and Head Patent Affairs at NOXXON Pharma AG. Mathias holds an MBA from ESCP Business School, a PhD in Biochemistry from Justus Liebig University Giessen, and a Diploma in Biochemistry from the University of Tübingen.
c-LEcta GmbH
c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, agenetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.